Latest Close
$1.34
Stock Hub
AIDX
20/20 Biolabs, Inc.
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
-$22.51 (-94.38%)
Market Cap
$14,043,320.00
Sector
Healthcare
Industry
Medical Devices
Recommendation
buy
52W Range
$1.26 to $50.00
Target Mean Price
$5.00
Beta
Not available
Trailing P/E
Not available
Forward P/E
Not available
Price / Book
Not available
Company Overview
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.